Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection (Q44117500)

30 November 2017

title

Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection (English)

1 reference

Simian immunodeficiency virus

30 November 2017

main subject

0 references

1 reference

1 reference

1

Richard Stebbings

1 reference

30 November 2017

Neil Berry

2

1 reference

30 November 2017

Jim Stott

3

1 reference

30 November 2017

Robin Hull

4

1 reference

30 November 2017

Barry Walker

5

1 reference

30 November 2017

Jenny Lines

6

1 reference

30 November 2017

William Elsley

7

1 reference

30 November 2017

Stuart Brown

8

1 reference

30 November 2017

Alison Wade-Evans

9

1 reference

30 November 2017

Gail Davis

10

1 reference

30 November 2017

Jenny Cowie

11

1 reference

30 November 2017

Meera Sethi

12

1 reference

30 November 2017

Neil Almond

13

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

30 November 2017

1 reference

30 November 2017

volume

330

1 reference

30 November 2017

issue

1

1 reference

30 November 2017

page(s)

249-260

1 reference

Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

In situ hybridization and immunolabelling study of the early replication of simian immunodeficiency virus (SIVmacJ5) in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Simian immunodeficiency virus Nef gene regulates the production of 2-LTR circles in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

In vivo resistance to simian immunodeficiency virus superinfection depends on attenuated virus dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Induction of mucosal homing virus-specific CD8(+) T lymphocytes by attenuated simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

The simian immunodeficiency viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Alternative interpretation of lymphocyte depletion studies using monoclonal antibodies in animals previously vaccinated with attenuated retroviral vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Mechanisms of protection against simian immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Live attenuated AIDS viruses as vaccines: promise or peril?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Macaques infected with attenuated simian immunodeficiency virus resist superinfection with virulence-revertant virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Mechanisms of protection induced by live attenuated simian immunodeficiency virus: III. Viral interference and the role of CD8+ T-cells and beta-chemokines in the inhibition of virus infection of PBMCs in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Mechanisms of protection induced by attenuated simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Emergence and kinetics of simian immunodeficiency virus-specific CD8(+) T cells in the intestines of macaques during primary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Dynamics of Simian immunodeficiency virus-specific cytotoxic T-cell responses in tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Presence of circulating CTL induced by infection with wild-type or attenuated SIV and their correlation with protection from pathogenic SHIV challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: correlation of CTL activity and reduction of cell-associated but not plasma virus load following challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

7 January 2021

Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

7 January 2021

Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

7 January 2021

Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

7 January 2021

Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.09.026

7 January 2021

10.1016/J.VIROL.2004.09.026

Identifiers

DOI

1 reference

30 November 2017

1 reference